Sensei Biotherapeutics, Inc.
SNSE
$6.55
$0.030.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.07M | 12.34M | 13.95M | 14.68M | 16.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.51M | 30.96M | 32.68M | 32.60M | 34.99M |
| Operating Income | -29.51M | -30.96M | -32.68M | -32.60M | -34.99M |
| Income Before Tax | -29.03M | -30.16M | -29.80M | -29.67M | -31.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.03 | -30.16 | -29.80 | -29.67 | -31.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.03M | -30.16M | -29.80M | -29.67M | -31.92M |
| EBIT | -29.51M | -30.96M | -32.68M | -32.60M | -34.99M |
| EBITDA | -28.48M | -29.64M | -31.36M | -31.28M | -33.66M |
| EPS Basic | -23.08 | -24.01 | -23.77 | -23.59 | -24.05 |
| Normalized Basic EPS | -13.92 | -14.42 | -15.09 | -14.97 | -15.18 |
| EPS Diluted | -23.08 | -24.01 | -23.77 | -23.59 | -24.05 |
| Normalized Diluted EPS | -13.92 | -14.42 | -15.09 | -14.97 | -15.18 |
| Average Basic Shares Outstanding | 5.03M | 5.02M | 5.01M | 5.03M | 5.30M |
| Average Diluted Shares Outstanding | 5.03M | 5.02M | 5.01M | 5.03M | 5.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |